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ABSTRACT
Langerhans cell histiocytosis (LCH) is a disease of unknown etiology, characterized by proliferation of pathological 
Langerhans cells within different organs. It mainly affects children, but adult cases also occur, with an incidence rate of one 
to two per million.  The head and neck are affected in almost 90% of cases. Diagnosis is made by means of histopatholo-
gical analysis, and imaging studies are necessary in order to determine extent of the disease.  There are no controlled trials 
proposing an optimal treatment protocol for LCH. Prognosis in adults is generally good due to the slow evolution of the 
disease and its favourable response to treatment. In our report, we present three cases of LCH in patients aged 16, 24, and 
28 years respectively, with primary manifestation in the maxillofacial area. A literature review was also conducted.   
Key words: Langerhans cell histiocytosis, LCH, histiocytosis X, lymphoproliferative disease.
RESUMEN
La Histiocitosis de Células de Langerhans (HCL), es una enfermedad de etiología desconocida, que se caracteriza por 
la proliferación e infiltración anormal, de órganos, por células de Langerhans patológicas. Afecta predominantemen-
te a pacientes en edad pediátrica, siendo en adultos la incidencia de la enfermedad de uno a dos casos por millón de 
habitantes. Las manifestaciones en cabeza y cuello aparecen en casi un 90% de los casos. El diagnóstico se obtiene por 
medios anatomopatológicos, siendo necesarias una serie de pruebas, determinantes de extensión, en todos los pacientes 
diagnosticados de HCL. No existen estudios, controlados, que determinen un tratamiento óptimo para la HCL. El pro-
nóstico de esta enfermedad en adultos es generalmente bueno debido a la lenta evolución de la enfermedad y a su buena 
respuesta al tratamiento. Presentamos una revisión de tres casos de HCL, de 16, 24 y 28 años de edad, con manifestación 
primaria en el área Maxilofacial. Así mismo, realizamos una revisión de la literatura.
Palabras clave: Histiocitosis de células de Langerhans, LCH, Histiocitosis X, enfermedad linfoproliferativa.
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INTRODUCTION
Langerhans cell histiocytosis (LCH) is a disease of unknown 
etiology, characterized by proliferation of  pathological 
Langerhans cells within different organs (1-4). In 1953, 
Lichtenstein observed cytoplasmic bodies, known as X 
bodies, within histiocytes from tissues of patients suffering 
from what were previously considered distinct clinical di-
sorders:  eosinophilic granuloma, Hand-Schüller-Christian 
disease and Abt-Letterer-Siwe disease (2,3,5-8).  As a result 
of their common underlying histopathology, Lichtenstein 
grouped these diseases together under the name of  his-
tiocytosis X.  With Nezelof´s discovery in 1973 that these 
histiocytes were in fact Langerhans cells, the disorder was 
renamed Langerhans cell histiocytosis (2,7).  LCH has 
also been referred to as Langerhans cell granulomatosis, 
histiocytosis X, Hashimoto-Pritzker’s syndrome, non lipidic 
reticuloendotheliosis, type II histiocytosis, or self-healing 
histiocytosis (2,9).
LCH has a slight predilection for males and generally ap-
pears in childhood (1,4,6,8). The incidence of the disease 
in the adult population is from one to two cases per million 
inhabitants, ranging in presentation from 15 to 91 years, with 
mean age of diagnosis 35 years (4,10). Although lesions may 
appear in tissues of varying origins such as skin, hypothala-
mus, liver, lung, or lymphoid tissue (4,6,8,11,12), bone is the 
most common site of the disease (3,13). The head and neck 
are involved in almost 90 % of cases, and may be the only 
areas affected (2). The skull is involved in 50 % of cases; the 
temporal bone, meatal skin and cervical lymphatic nodes 
in 20-25 % of cases, while maxillary and mandibular bones 
are affected in 5 to 10 % of cases (2). 
The Writing Group of the Histiocyte Society has identified 
three levels of  confidence in the diagnosis of   LCH, as 
follows: a presumptive diagnosis can be made when light 
morphologic characteristics are consistent with the findings 
defined in the literature for LCH; a designated diagnosis 
when, besides consistent light morphologic features, two 
or more supplemental positive stains for adenosinetriphos-
phatase, S-100 protein, alpha-D-mannosidase or peanut 
lectin are also present; and a definitive diagnosis when, 
besides light morphologic characteristics, Birbeck granules 
are detected in the lesional cell using electron microscopy 
and/or there is a positive staining for CD1a antigen (T6) on 
the surface of lesional cells (1,4). Once the condition has 
been diagnosed, adequate workup to determine the extent 
of the disease is mandatory (8,10). There are no controlled 
studies establishing optimal treatment for LCH (2,7,9,10). 
Prognosis of LCH in adults is generally good due to the 
slow evolution of the disease and its favourable response 
to treatment (11).
CLINICAL CASE REPORTS. (TABLE 1)
Case 1. A 24-year-old female was referred to the Dept. of 
Oral and Maxillofacial Surgery with a one-month history of 
swelling of the right upper eyelid, causing convex distortion 
of the eyebrow and adjacent frontal area.   The lesion was 
elastic to the touch, painful, and impeded normal upper 
eyelid movement (Fig.1. A). Radiographic imaging showed a 
lobulated, lytic lesion in the right fronto-supraorbital region, 
with ground-glass appearance.  There was no evidence of 
periosteal reaction or marginal sclerosis. Further exami-
nation with cranial MRI revealed the lesion to be 2.5 cm 
in diameter, circumscribed and cystic, with adjacent bone 
destruction in the right supraorbital area (Fig.1.C and D). 
Bone scintigraphy showed a single, hypercaptating lesion in 
the right supraorbital region. Biopsy revealed the diagnosis 
of LCH.  After adequate workup to determine the extent of 
the disease, no other lesions were encountered. Resection 
was performed by superolateral orbitotomy, using a com-
bined craniofacial approach. The resulting bony defect in 
the orbital roof and lateral orbital wall was grafted with 
calvarial bone and fixed by means of miniplates (Fig.1. B). 
Four years following surgery, the patient was diagnosed with 
hypogonadotropic hypogonadism and diabetes insipidus. 
Nine years post-surgery, there are no signs of recurrence 
of the lesion.
Case 2. A 16-year-old male was referred to the Dept. of Oral 
and Maxillofacial Surgery, affected by a sudden proptosis 
of the right eye with restriction of ocular movements, eyelid 
swelling and conjunctival hyperemia.  CT scan showed a 
3.5 cm mass in the superolateral region of the right orbit, 
making contact with the posterosuperior part of the right 
eyeball and right optic nerve, and spreading through the 
orbital roof into the anterior cranial fossa (Fig.2. A). A 
well-defined, hypercaptating, heterogeneous lesion was 
observed in the superolateral region of the right orbit on 
MRI (Fig.2. B). Biopsy revealed the diagnosis of  LCH. 
Bone scintigraphy showed pathological focal hypercaptation 
in the area of the lesion, the latter resected by means of a 
combined craniofacial approach. A bicoronal flap was eleva-
ted and an orbito-zygomatic osteotomy exposed the tumor 
(Fig.2.C). After en bloc resection of the tumor, the orbital 
walls were reconstructed with outer-table calvarial bone 
grafts. Resorbable miniplates (Polimax ®) were employed 
to fix the grafts and the bone flaps (Fig.2.D). One and a 
half  years following surgery, there are no signs of relapse, 
nor complications associated with LCH.
Case 3. A 28-year-old male with previous history of right 
upper jaw odontogenic cyst removal at the site of dental pieces 
15 and 16, with exodontia of same due to mobility.  Three 
months following said intervention, the patient presented with 
pain and swelling in the treated area.  An orthopantomogram 
showed extensive bone loss with respect to previous radiogra-
phs, involving right maxillary mesial surface of 17 to distal 
surface of 12 (Fig.3.A).  The lesion was resected once again, 
and the histopathological report revealed LCH.  Bone scin-
tigraphy showed no other lesions. Four months following the 
second surgery, the patient presented with trismus, swelling 
and pain in the left upper jaw and in right and left mandibular 
bodies. On the orthopantomogram, new cystic lesions were 
observed in the regions of dental pieces 25, 36 to 37, and 46 
to 48, with affectation of these teeth (Fig.3. B). Cystectomy 
of mandibular lesions was performed, as well as exodontia 
of dental pieces 36, 37, 46, 47 and 48 due to mobility. 
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Fig. 1. 1. Case 1: A: preoperative appearan-
ce; B:  postoperative appearance; C:  MRI, 
coronal view; D:  MRI, sagittal view.
CASE 1 CASE 2 CASE 3
AGE 24 16 28 
GENDER Female Male Male 
SITE Superolateral area of right orbit. Superolateral area of right orbit. Right upper maxilla  (from 12 to 17). 
SIZE 
(largest diameter) 2.5 cm 3.5 cm 5 cm 
CLINICAL
MANIFESTATIONS
Rapidly growing mass. Headache. 
Eyelid edema. 
Sudden proptosis. Limited ocular 
mobility. Eyelid edema. 




Simple radiographs, MRI, bone 
scintigraphy, biopsy. CT, MRI, bone scintigraphy, biopsy. Waters’, Orthopantomogram. 
RADIOLOGICAL FINDINGS
Rx: ground-glass image. 
MRI: cystic lesion. Intense peripheral 
uptake.
Bone scintigraphy: hypercaptation in 
area of lesion. 
CT: mass of higher density than brain, 
with intense uptake after contrast. 
MRI: isointense signal with respect to 
brain parenchyma, both in T1 and T2. 
Orthopantomogram: bone loss. 
T 1 MONTH 1 DAY 1 WEEK 
CONJOINT SURGERY* YES YES NO 
APPROACH Bicoronal approach. Frontoorbital osteotomy. 
Bicoronal approach. 
Frontoorbitozygomatic osteotomy. Intraoral. 
RECONSTRUCTION YESCalvarial bone flap. 
YES
Calvarial bone flap. NO
EVOLUTION FOLLOWING
SURGERY
No evidence of bone recurrence after 
nine years of disease evolution. 
Diabetes insipidus and 
hypogonadotropic hypogonadism four 
years following orbital surgery. 
No evidence of bone recurrence 
following one year of disease 
evolution. 
Multiple maxillary, mandibular and 
malar recurrences. Currently 
undergoing chemotherapy. 
Table 1. T: time elapsed between first symptoms and first consultation.
*:  Dept. of Oral and Maxillofacial Surgery and Dept. of Neurosurgery.  
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Fig. 3. Case 3: Orthopantomograms (arrows indicating hypodense lesions): A: from first consultation; B: four months following first 
consultation; C: seven months following first consultation; D: ten months following first consultation. 
Fig. 2. Case 2: A: CT, axial view, where a mass is visible in the supero-lateral region of the right orbit; B:  MRI coronal view, where 
a well-defined lesion with an intense and heterogeneous signal is observed; C:  intraoperative image following orbitozygomatic 
osteotomy. Eyeball and frontal lobe are visible; D:  fixation of the bone flap and reconstruction of the orbital roof (calvarial 
bone graft) with resorbable miniplates. 
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 The postoperative histopathological report revealed LCH. 
Subsequently, two additional surgeries were undertaken due 
to the appearance of new lesions in the right malar bone, 
right and left hemimaxillae, and left mandibular body (Fig.3. 
C). When yet more new lesions were discovered in the right 
mandibular angle, ramus and body (Fig.3. D), we decided to 
initiate chemotherapy treatment.  The first phase of therapy 
consisted of intravenous vinblastine (6g/m2/week, with a 
total dose of 110g, in 11 cycles of 10 g each), with a second 
phase of oral methotrexate (2.5mg/3 times/week), which 
is currently being administered to the patient.  A positive 
clinical and radiological response was observed soon after 
beginning chemotherapy 11 months ago, with no sign of 
recurrence of the lesions to date.       
DISCUSSION
The etiopathogenesis of  LCH is unknown, although it 
appears to be linked to a disturbance in immune system re-
gulation (2,3,8,12-14). In spite of being considered a disease 
of sporadic appearance, some authors have postulated the 
existence of a familiar predisposition (4,8,14). 
Manifestation of LCH may take various forms.  In the maxi-
llofacial area, skin affectation may appear as a papular rash; 
scalp involvement has a seborrhoea-like presentation.  Oral 
mucosa affectation, although infrequent, is characterized 
by gingival hypertrophy and ulcers of the buccal mucosa, 
hard and soft palates, and tongue (8,10,13). Osseous invol-
vement is observed in 78% of patients, the cranium being 
the bone most commonly affected (49%).  Bony lesions of 
the maxillomandibular area are also frequent, occurring in 
30% of adult cases, particularly affecting posterior regions 
of the mandible (7,8,14).  Pain and swelling of the mandi-
ble, with mobility and loss of teeth, may be the presenting 
symptoms of the disease (1,3,6,8,11,14). Intraorbital invol-
vement can produce proptosis (3,8), as occurred in Case 2 
of this report.  The lymphatic system may be affected, with 
enlargement of  lymphatic ganglions, Waldeyer´s ring or 
the thymus (2,8). Other soft tissues have been reported to 
be affected in the head and neck area, such as the eyelids, 
parotid and submandibular glands, the external auditory 
canal, the middle ear, the thyroid and the gastrointestinal 
tract (5,8,15).       
Plain radiographs show LCH bony lesions as non-calcified, 
lytic areas without peripheral sclerosis. The radiological ima-
ge of “floating teeth” is typical of maxillary and mandibular 
involvement (2,3,5,11,14,16). The differential diagnosis of 
mandibular lesions must include odontogenic cysts and 
tumors, primary bone tumors, osteomyelitis, metastases, 
multiple myeloma and giant cell granuloma (2,11,14). 
Radiographic imaging of lytic lesions of the skull reveals a 
punched-out pattern without evidence of periosteal reaction 
or marginal sclerosis, known as “geographic skull” (2,11). 
In some cases, a central mass of residual bone can be seen 
within the lytic lesion, giving the appearance of a “bull´s 
eye”, alternatively referred to as a “button sequestrum” 
or a “hole within a hole” (3).  The soft tissue mass accom-
panying all osseous lesions can best be seen with CT scan 
and MRI (3), the latter showing a well-defined area of soft 
tissue surrounding a focal lesion, with altered bone marrow 
signal (2). Scintigraphy is useful for evaluating extent of the 
disease and for monitoring its evolution (7).
Histological features of  LCH lesions include, besides 
Langerhans cells, the presence of  a variable number of 
eosinophils, neutrophils, mononuclear and polynuclear 
histiocytes, and lymphocytes (1,3,6,8,11). Initial stage 
lesions tend to be very cellular, whereas in more advanced 
stages, a higher degree of fibrosis is present (6). Histological 
appearance does not correlate with clinical behaviour (11). 
Langerhans cells are oval or rounded in shape, pale, and have 
a predominantly eosinophilic cytoplasm (2,8). The nucleus 
is oval or lobulated, with a typical central sulcus, giving a 
“coffee bean” appearance.  Birbeck’s granules, which can 
be seen inside Langerhans cells with electron microscopy, 
are pathognomonic for LCH (8,11). These are trilamellar, 
cytoplasmatic structures with either an elongated or tennis 
racket shape (if  there is dilation of one end), characterized 
by periodic zipper-like striations (11). Langerhans cells also 
express S-100 protein, ATP-ase, peanut lecithin, alpha-D-
mannosidase, and antigens CD 207 and CD1a (2,3,8,14). 
Multiple therapeutic modalities have been suggested for 
the treatment of  LCH, such as curettage, resection, ra-
diotherapy, chemotherapy, and intralesional and systemic 
corticosteroids (8,11,12). For patients with monostotic 
disease, some authors recommend therapeutic abstention, 
since spontaneous regression takes place in the majority 
of these cases.  Others advocate surgical treatment of the 
lesion by means of  curettage or biopsy (4,6,7,11,12,14), 
or intralesional injection of corticosteroids (2,6,11,12,14). 
Radiotherapy, in doses of 1,200 to 1,800 cGys, has been 
proposed for non-accessible lesions, for those which com-
promise vital structures such as the optic nerve, and for 
recurrence of  previously resected lesions (6,9,11). When 
lymphatic nodes are involved, the most adequate treatment 
is excision of affected nodes.  In cases of skin manifestation 
only, topical steroids and intralesional interferon-beta can 
be employed (6,17), although success with oral thalidomide 
has also been obtained in cutaneous LCH (8).  Oral mucosal 
lesions without underlying bone disease respond well to 
perilesional infiltration of triamcinolone acetonide (13).
For patients with multiple LCH lesions, there is no univer-
sally accepted single treatment strategy.  Some clinicians 
advocate aggressive, generalized treatment in these cases, 
whereas others suggest a conservative, symptomatic appro-
ach, unless there are systemic manifestations such as pain, 
fever, failure to thrive or disorders of vital organs.  While 
radiation alone, or single-drug administration have been 
shown to be insufficient for treatment of  multiple bony 
lesions, most of these patients respond to therapy with a 
combination of steroids and cytotoxic agents (2,18). For 
example, the rate of recurrence of the disease falls markedly 
with 6-month treatments of  prednisone and vinblastine. 
Other studies defend the effectiveness of 2-chloro-2´-deox-
yadenosine (2CdA) in patients with recurrent and multisys-
temic affectation (8,10). 
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 In terms of prognosis, both unifocal and multifocal lesions 
respond well to treatment, with cure rates of up to 80%. 
However, 20% of patients develop a more aggressive, mul-
tiorganic affectation which requires repeated treatments, 
and produces a 9% mortality rate (8,11). In the majority of 
refractory or life-threatening cases, there is lung involvement 
(11), with a worse prognosis for isolated lung affectation 
than for multisystemic disease, even if  there are lung lesions 
in the latter case (4). In contrast, cases with isolated bone 
involvement have cure rates of 97% (11). The overall 5-year 
survival rate for LCH is approximately 92.3% (4).
In all three cases presented in this report, the lesions were 
surgically resected. In Cases 1 and 2, there has been no 
evidence of local relapse in 9 years and 1 year of disease 
evolution, respectively.   However, in Case 3, due to the rapid 
and multiple bony relapses in the maxillofacial area follo-
wing surgeries, we administered chemotherapy consisting of 
vinblastine and methotrexate, with favourable results. 
Given the rarity of LCH, we strongly recommend protoco-
lization of treatment.  To further this end, patients suffering 
from this disease, particularly those with multiorganic 
affectation, should be included in clinical trials carried out 
by the Histiocytosis Society.
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